ClinicalTrials.gg
Active, not recruitingNCT04971226Updated Aug 28, 2026Results posted

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

A Phase 3 interventional study of Imatinib and Nilotinib in Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 110 sites in 29 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
2nd of 21
405 · median 100
Started
2021
with 4 others
Phase 3
5 of 21
none open now
Primary completion
2023-11
later than 0 of 12 live
Registered
11th of 21
by date
Lead sponsor
12 of 21
Novartis Pharmaceuticals

Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 11th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About asciminib

asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD.

This study has three periods: 1. Treatment period for all randomized participants, 2. Optional Treatment-Free Remission (TFR) period only for participants meeting TFR eligibility criteria and 3. Treatment Re-Initiation (TRI) period only for participants who relapsed after TFR attempt.

Read the detailed description

This study is a phase III, multi-center, open-label, randomized study of oral asciminib 80 mg QD versus Investigator selected TKI (imatinib, nilotinib, dasatinib, or bosutinib) in adult patients with newly diagnosed Ph+ CML-CP. All comparator TKIs will be made available, unless not permitted by local regulations or local Health Authority or not approved for the treatment of CML in the country.

Approximately 402 patients will be randomized in a 1:1 ratio to asciminib and Investigator selected TKI to join the treatment period.

Randomization will be stratified based on the following two stratification factors:

  • ELTS score (low versus intermediate versus high)
  • Pre-randomization selected TKI (imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib)).

Prior to randomization, the Investigator, in consultation with the patient, considering the current treatment paradigm and patient characteristics and comorbidities, will make a selection of preference for imatinib or 2G TKI (nilotinib or dasatinib or bosutinib) if the patient is randomized to the comparator arm. The stratified randomization based on these two stratification factors will help to achieve a balance across the treatment arms for the possible comorbidities and baseline characteristics of patients enrolled in the study.

To further ensure that the distribution of patients, between imatinib and 2G TKIs (nilotinib or dasatinib or bosutinib), in the Investigator selected TKI arm is reflective of the use of these agents in clinical practice, the enrollment into the strata of imatinib versus 2G TKI (nilotinib or dasatinib or bosutinib) based on the pre-randomization selection of TKI will be managed by Interactive Response Technology to be approximately 50% versus 50%.

Treatment arms: The study will have 2 treatment arms:

  • Arm 1: asciminib 80 mg QD under fasting conditions
  • Arm 2: Investigator selected TKI that will include one of the below treatments:
  • Imatinib 400 mg QD administered with food
  • Nilotinib 300 mg BID administered under fasting conditions
  • Dasatinib 100 mg QD administered with or without meal
  • Bosutinib 400 mg QD administered with food.

Apart from the treatment period described above, the present study comprises an optional Treatment-Free Remission (TFR) Period enrolling consenting participants of the treatment period (receiving asciminib or IS-TKI) who will discontinue their randomized treatment if they meet per protocol eligibility criteria. The optional TFR Period will last at least 2 years to assess the feasibility of TFR and TFR outcomes following discontinuation of their randomized treatment (asciminib or IS-TKI).

In addition, during the TFR Period, participants who will lose major molecular response (MMR) must re-initiate treatment and will enter into a Treatment Reinitiation (TRI) Period.

During the treatment period, no crossover of study treatment across arms and no change of study treatment within the Investigator selected TKI will be allowed. For specifically participants who must transition into the TRI Period, at the time of treatment re-initiation: a) participants who were previously treated with asciminib will resume asciminib at the same dose prior to entry into TFR. b) participants who were on IS-TKI may either continue with the same study treatment they were randomized to and at the same dose prior to entry into TFR or may switch to asciminib with a starting dose of 80 mg QD.

Duration of Study treatment: Patients on the study will continue to receive the assigned treatment until the End of Study, premature discontinuation due to treatment failure, disease progression or intolerance, due to Investigator or participant decision. or due to patient going to TFR Period and/or TRI Period.

Duration of study: The End of Study will occur 8 years from the last patient first treatment in the study. Patients who discontinue study treatment prematurely due to any reason, will be followed up for survival and progression (to AP/BC) until the End of Study.

03

Conditions studied

  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Keywords

  • Asciminib
  • Chronic Myeloid Leukemia
  • CML
  • Philadelphia Chromosome
  • TKIs
  • Bosutinib
  • Dasatinib
  • Nilotinib
  • Imatinib
  • Treatment-free remission
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for treatment period:

Participants eligible for inclusion in this study must meet all of the following criteria:

  • Male or female patients ≥ 18 years of age.
  • Participants with CML-CP within 3 months of diagnosis.
  • Diagnosis of CML-CP (ELN 2020 criteria) with cytogenetic confirmation of Philadelphia chromosome

Documented chronic phase CML will meet all the below criteria (Hochhaus et al 2020):

  • \< 15% blasts in peripheral blood and bone marrow,
  • \< 30% blasts plus promyelocytes in peripheral blood and bone marrow,
  • \< 20% basophils in the peripheral blood,
  • count ≥ 100 x 10\^9/L (≥ 100,000/mm\^3),
  • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly.

    • (ECOG) performance status of 0 or 1.
    • Adequate end organ function as defined by:
  • Total \< 3 x ; patients with Gilbert's syndrome may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
  • (CrCl) ≥ 30 mL/min as calculated using Cockcroft-Gault formula,
  • Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not and not associated with risk factors for acute pancreatitis

    - Participants must have the following laboratory values within normal limits or corrected to within normal limits with supplements prior to randomization:

  • Potassium (potassium increase of up to 6.0 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min)
  • Total calcium (corrected for serum albumin); (calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with CrCl* ≥ 90 mL/min)
  • Magnesium (magnesium increase of up to 3.0 mg/dL or 1.23 mmol/L if associated with CrCl* ≥ 90 mL/min)
  • For patients with mild to moderate renal impairment (CrCl* ≥ 30 mL/min and \<90 mL/min) - potassium, total calcium (corrected for serum albumin) and magnesium should be ≥ LLN or corrected to within normal limits with supplements prior to randomization.
  • *CrCl as calculated using Cockcroft-Gault formula

    • Ability to provide written prior to any study related screening procedures being performed.
    • Evidence of typical BCR-ABL1 transcript [e14a2 and/or e13a2] at the time of screening which is amenable to standardized Real time quantitative polymerase chain reaction (RQ-PCR) quantification.

Exclusion Criteria for Treatment period:

  • Previous treatment of CML with any other anticancer agents including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide. Treatment with either imatinib, or nilotinib, or dasatinib or bosutinib for ≤2 weeks is allowed, but no other treatment with other tyrosine kinase inhibitors prior to randomization is permitted.
  • Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required).
  • Impaired cardiac function or cardiac repolarization abnormality including but not limited to any one of the following:

    • History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)
    • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block)
    • ≥ 450 ms (male patients), ≥460 ms (female patients) on the average of three serial baseline (using the QTcF formula) as determined by central reading. If QTcF ≥ 450 ms and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
    • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
    • Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
    • Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org/ that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.•Inability to determine the QTcF interval
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection; uncontrolled arterial or pulmonary hypertension, uncontrolled clinically significant hyperlipidemia). Please refer to Section 6.3.1
  • History of significant congenital or acquired bleeding disorder unrelated to cancer.
  • Major surgery within 4 weeks prior to study entry or who have not recovered from prior surgery.
  • History of other active within 3 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
  • History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis.
  • History of chronic liver disease leading to severe hepatic impairment, or ongoing acute liver disease.
  • Known to the study treatment

Other protocol-defined Inclusion/exclusion criteria will apply.

Inclusion Criteria for optional TFR period:

Participants meeting the following additional criteria are not eligible to enter the TRI Period:

  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
  • A minimum of 5 years of study treatment up to maximum of 6 years of study treatment (i.e. participants are eligible to enter TFR any time between year 5 and year 6 of their study treatment
  • Sustained MR 4.0 (BCR::ABL1 IS ≤0.01%) or better, assessed by central laboratory for at least 2 years (equivalent to 104 weeks) which includes MR 4.5 (BCR::ABL1 IS ≤0.0032%) for at least 1 year (equivalent to 52 weeks) immediately prior to entry into the TFR Period, with the 5 last consecutive RQ-PCR (every 12 weeks) assessments at/or below MR 4.5. Entry into TFR Period should be no later than 12 weeks from the last MR 4.5 RQ-PCR assessment
  • Separate signed informed consent must be obtained prior to participation in the TFR Period

Exclusion Criteria for optional TFR period:

  • Participants meeting the following additional criterion are not eligible for the inclusion in the optional TFR Period:
  • Participants in the treatment re-initiation (TRI) Period cannot re-enter TFR for a second TFR attempt

Exclusion Criteria for Treatment Re-initiation (TRI) Period

Participants meeting the following additional criterion are not eligible to enter the TRI Period:

  • In case of a pregnancy during the TFR Period, the pregnant woman must be discontinued upon loss of MMR (>0.1% BCR::ABL1 IS at a single assessment) and cannot enter the TRI Period
  • Impaired cardiac function or cardiac repolarization abnormality
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Asciminib

    Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs

    Drug: Asciminib

  • Active comparator
    Investigator selected TKIs

    Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments: Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food

    Drug: Imatinib · Drug: Nilotinib · Drug: Bosutinib · Drug: Dasatinib

Interventions

  • Comes in 100 mg and 400 mg tablets and taken orally

    Also known as: STI571

  • Comes in 150 mg and 200 mg capsules and taken orally

    Also known as: AMN107

  • Comes in 100 mg and 400 mg tablets and taken orally

  • Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally

  • Comes in 40 mg tablets and taken orally

    Also known as: ABL001

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI

    Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    Time frame: At 48 weeks

  2. Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)

    Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL1/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    Time frame: At 48 weeks

Secondary outcomes

  1. Major Molecular Response at Week 96

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    Time frame: at 96 weeks (96 weeks after last patient first dose)

  2. Time to Discontinuation of Study Treatment Due to Adverse Events (TTDAE)

    TTDAE is defined as the time from the date of first dose of study treatment to the date of discontinuation of study treatment due to Adverse Event (AE). For patients ongoing without study treatment discontinuation, on or prior to the analysis cut-off date, the time will be censored at the at the analysis cut-off date.

    Time frame: 96 weeks after last patient first dose

  3. Major Molecular Response at Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    Time frame: Planned total follow-up duration of 5 years

  4. Major Molecular Response by Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

    Time frame: Planned total follow-up duration of 5 years

  5. MR4.0 at Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).

    Time frame: Planned total follow-up duration of 5 years

  6. MR4.5 at All Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).

    Time frame: Planned total follow-up duration of 5 years

  7. MR4.0 by Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).

    Time frame: Planned total follow-up duration of 5 years

  8. MR4.5 by All Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).

    Time frame: Planned total follow-up duration of 5 years

  9. Complete Hematological Response (CHR) at All Scheduled Data Collection Time Points

    Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver

    Time frame: Planned total follow-up duration of 5 years

  10. Complete Hematological Response (CHR) by All Scheduled Data Collection Time Points

    Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver

    Time frame: Planned total follow-up duration of 5 years

  11. Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96

    The CCyR response status was to be based on bone marrow assessment. Bone marrow examination for cytogenetic assessment was to be performed locally by the Investigator at baseline for all participants. Thereafter, during the course of the study, cytogenetic assessment was not mandatory and only performed if clinically indicated.

    Time frame: By week 48 and by week 96 (48 weeks and 96 weeks after last patient first dose); data collection/analysis is ongoing for the 96 week time point, and the data will be reported later

  12. Duration of MMR

    Duration of MMR is defined as the time between the date of the first documented achievement of MMR and the earliest date of loss of MMR, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

    Time frame: Planned total follow-up duration of 5 years

  13. Duration of MR4.0

    Duration of MR4.0 is defined as the time between the date of the first documented achievement of MR4.0 and the earliest date of loss of MR4.0, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

    Time frame: Planned total follow-up duration of 5 years

  14. Duration of MR4.5

    Duration of MR4.5 is defined as the time between the date of the first documented achievement of MR4.5 and the earliest date of loss of MR4.5, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

    Time frame: Planned total follow-up duration of 5 years

  15. Time to First MMR

    Time to first MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MMR.

    Time frame: Planned total follow-up duration of 5 years

  16. Time to First MR4.0

    Time to first MR4.0 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.0. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.0.

    Time frame: Planned total follow-up duration of 5 years

  17. Time to First MR4.5

    Time to first MR4.5 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.5. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.5.

    Time frame: Planned total follow-up duration of 5 years

  18. BCR-ABL1≤1% at Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.

    Time frame: Planned total follow-up duration of 5 years

  19. BCR-ABL1≤1% by Scheduled Data Collection Time Points

    Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.

    Time frame: Planned total follow-up duration of 5 years

  20. Time to Treatment Failure (TTF)

    TTF is defined as the time from date of randomization to the first/earliest documented date of any of the following events: treatment failure as per ELN, Confirmed loss of MMR while on study treatment, discontinuation from study treatment due to any reason For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the last study assessment date while on treatment, or the EOT (whichever comes first) .

    Time frame: Planned total follow-up duration of 5 years

  21. Failure Free Survival (FFS)

    FFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure per ELN, confirmed loss of MMR, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

    Time frame: Planned total follow-up duration of 5 years

  22. Event Free Survival (EFS)

    EFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure as per ELN, confirmed loss of MMR ,discontinuation of study treatment due to AE, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

    Time frame: Planned total follow-up duration of 5 years

  23. Progression Free Survival (PFS)

    PFS is defined as the time from the date of randomization to the earliest occurrence of progression to AP/BC or death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

    Time frame: Planned total follow-up duration of 5 years

  24. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last contact before the cut-off date.

    Time frame: Planned total follow-up duration of 5 years

  25. Trough Plasma Concentrations.

    Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.

    Time frame: Week 48

  26. Pharmacokinetics (PK) of Asciminib: Cmax

    Cmax is the maximum serum concentration of asciminib during a dosing interval (mass x volume-1).

    Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)

  27. PK of Asciminib: Tmax

    Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)

    Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)

  28. PK of Asciminib: AUCtau and AUClast

    AUCtau is the area under the plasma concentration-time curve over the dosing interval. AUClast is the area under the plasma concentration-time curve from time zero (time of dose administration) to time of last measurable concentration (mass x time x volume-1)

    Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)

  29. PK of Asciminib: CL/F

    CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).

    Time frame: Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)

  30. Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96

    The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses the quality of life of cancer patients. It consists of functioning scales, symptom scales, and the global health status quality of life (QoL) scale. A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.

    Time frame: Baseline, week 48 and week 96

  31. Change From Baseline in EORTC QLQ-CML24 Scales at Week 48 and Week 96

    The QLQ-CML24 consists of multi-scale items: symptom burden, impact on worry/mood, impact on daily life, body image problems, satisfaction with care and information and satisfaction with social life. A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.

    Time frame: Baseline, week 48 and week 96.

07

Results

Posted Mar 10, 2025
Limitations and caveats
Adverse Events data were not collected from the 4 participants who are not included in the Safety Set as they did not receive any treatment.

Participant flow

All trial participants randomized in a 1:1 ratio between asciminib and investigator selected TKI (imatinib 400 mg QD, nilotinib 300 mg BD, dasatinib 100 mg QD or bosutinib 400 mg QD).

Participant flow — Overall Study
MilestoneAsciminib (Imatinib Stratum)Asciminib (2nd Generation TKI Stratum)Investigator Selected TKI (Imatinib Stratum)Investigator Selected TKI (2nd Generation TKI Stratum
Started101100102102
Participants not treated1021
Treated100100100101
Completed85886377
Not completed16123925
Withdrew: Unsatisfactory therapeutic effect662110
Withdrew: Adverse event651110
Withdrew: Progressive disease2031
Withdrew: Protocol deviation1011
Withdrew: Subject decision0111
Withdrew: Pregnancy0001
Withdrew: Participants not treated1021

Outcome measures

PrimaryPercentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI

Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

Time frame:
At 48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI
ParticipantsAsciminib (All Asciminib )Investigator Selected TKI (All Comparators)
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI136100
Statistical analysis
  • Asciminib (All Asciminib ) vs Investigator Selected TKI (All Comparators) · Mantel Haenszel · p = <0.001 · Risk difference (rd): 18.88 · 95% CI 9.59 to 28.17The Estimate Value is a percentage.
SecondaryMajor Molecular Response at Week 96

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

Time frame:
at 96 weeks (96 weeks after last patient first dose)

Results for this outcome have not been posted.

SecondaryTime to Discontinuation of Study Treatment Due to Adverse Events (TTDAE)

TTDAE is defined as the time from the date of first dose of study treatment to the date of discontinuation of study treatment due to Adverse Event (AE). For patients ongoing without study treatment discontinuation, on or prior to the analysis cut-off date, the time will be censored at the at the analysis cut-off date.

Time frame:
96 weeks after last patient first dose

Results for this outcome have not been posted.

SecondaryMajor Molecular Response at Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryMajor Molecular Response by Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryMR4.0 at Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryMR4.5 at All Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryMR4.0 by Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.0 is defined as a ratio BCR-ABL/ABL ≤0.01% on the international scale (ie, at least 4 log reduction from a standardized baseline value).

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryMR4.5 by All Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction. MR4.5 is defined as a ratio BCR-ABL/ABL ≤0.0032% on the international scale (ie, at least 4.5 log reduction from a standardized baseline value).

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryComplete Hematological Response (CHR) at All Scheduled Data Collection Time Points

Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryComplete Hematological Response (CHR) by All Scheduled Data Collection Time Points

Hematologic response will be assessed by CBC and physical examination at each visit. Complete Hematological Response (CHR) will be defined as all of the following present for ≥ 4 weeks: white blood cell(s) (WBC) count \< 10 x 10\^9/L PLT count \< 450 x 10\^9/L Basophils \< 5% No blasts and promyelocytes in peripheral blood Myelocytes + metamyelocytes \< 5% in peripheral blood No evidence of extramedullary disease, including spleen and liver

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96

The CCyR response status was to be based on bone marrow assessment. Bone marrow examination for cytogenetic assessment was to be performed locally by the Investigator at baseline for all participants. Thereafter, during the course of the study, cytogenetic assessment was not mandatory and only performed if clinically indicated.

Time frame:
By week 48 and by week 96 (48 weeks and 96 weeks after last patient first dose); data collection/analysis is ongoing for the 96 week time point, and the data will be reported later
Reported as:
Count of participants · Participants
Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96
ParticipantsAsciminib (All Asciminib )Investigator Selected TKI (All Comparators)
Complete cytogenetic response (CCyR)10
Partial cytogenetic response (PCyR)10
Minor cytogenetic response (mCyR)00
Minimal cytogenetic response00
No cytogenetic response00
SecondaryDuration of MMR

Duration of MMR is defined as the time between the date of the first documented achievement of MMR and the earliest date of loss of MMR, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryDuration of MR4.0

Duration of MR4.0 is defined as the time between the date of the first documented achievement of MR4.0 and the earliest date of loss of MR4.0, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryDuration of MR4.5

Duration of MR4.5 is defined as the time between the date of the first documented achievement of MR4.5 and the earliest date of loss of MR4.5, treatment failure, progression to Accelerated Phase/Blast Crisis, or CML-related death

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryTime to First MMR

Time to first MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MMR.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryTime to First MR4.0

Time to first MR4.0 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.0. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.0.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryTime to First MR4.5

Time to first MR4.5 is defined as the time from the date of randomization to the date of the first documented occurrence of MR4.5. Time will be censored at the last molecular assessment date while on treatment, or the End Of Treatment (whichever comes first) for patients who have not experienced MR4.5.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryBCR-ABL1≤1% at Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryBCR-ABL1≤1% by Scheduled Data Collection Time Points

Molecular response is assessed using BCR-ABL transcript levels measured by realtime quantitative polymerase chain reaction.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryTime to Treatment Failure (TTF)

TTF is defined as the time from date of randomization to the first/earliest documented date of any of the following events: treatment failure as per ELN, Confirmed loss of MMR while on study treatment, discontinuation from study treatment due to any reason For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the last study assessment date while on treatment, or the EOT (whichever comes first) .

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryFailure Free Survival (FFS)

FFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure per ELN, confirmed loss of MMR, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryEvent Free Survival (EFS)

EFS is defined as the time from the date of randomization to the earliest occurrence of the following events: treatment failure as per ELN, confirmed loss of MMR ,discontinuation of study treatment due to AE, progression to AP/BC, death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the date of randomization to the earliest occurrence of progression to AP/BC or death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last study treatment assessment or last post-treatment follow-up.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as the time from the date of randomization to the date of death from any cause. For patients that have not experienced an event prior to or at the analysis cut-off date, the time will be censored at the date of last contact before the cut-off date.

Time frame:
Planned total follow-up duration of 5 years

Results for this outcome have not been posted.

SecondaryTrough Plasma Concentrations.

Trough plasma concentration will measure the concentration of asciminib in the blood immediately before the next dose is administered.

Time frame:
Week 48
Reported as:
Median · ng/mL
Trough Plasma Concentrations.
ng/mLAsciminib (All Asciminib )
Trough Plasma Concentrations.161 (11.9 to 1010)
SecondaryPharmacokinetics (PK) of Asciminib: Cmax

Cmax is the maximum serum concentration of asciminib during a dosing interval (mass x volume-1).

Time frame:
Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK) of Asciminib: Cmax
ng/mLAsciminib (All Asciminib)
Pharmacokinetics (PK) of Asciminib: Cmax1470 ± 38.2
SecondaryPK of Asciminib: Tmax

Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (time)

Time frame:
Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
Reported as:
Median · Hour (hr)
PK of Asciminib: Tmax
Hour (hr)Asciminib (All Asciminib)
PK of Asciminib: Tmax2.00 (0.883 to 3.18)
SecondaryPK of Asciminib: AUCtau and AUClast

AUCtau is the area under the plasma concentration-time curve over the dosing interval. AUClast is the area under the plasma concentration-time curve from time zero (time of dose administration) to time of last measurable concentration (mass x time x volume-1)

Time frame:
Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
Reported as:
Geometric mean · ng*hr/mL
PK of Asciminib: AUCtau and AUClast
ng*hr/mLAsciminib (All Asciminib)
AUClast8590 ± 42.2
AUCtauNA ± NA
SecondaryPK of Asciminib: CL/F

CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).

Time frame:
Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
Reported as:
Geometric mean · ng*hr/mL
PK of Asciminib: CL/F
ng*hr/mLAsciminib (All Asciminib)
PK of Asciminib: CL/FNA ± NA
SecondaryChange From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96

The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses the quality of life of cancer patients. It consists of functioning scales, symptom scales, and the global health status quality of life (QoL) scale. A high score for functional and QoL items/scales from the QLQ-30 represents better function and QOL. A high score in symptoms items from QLQ-30 represents worse symptoms.

Time frame:
Baseline, week 48 and week 96
Reported as:
Count of participants · Participants
Change From Baseline in Overall Scores (Global Health Status) and Individual Scales of the EORTC QLQ-C30 at Week 48 and Week 96
ParticipantsAsciminib (All Asciminib )Investigator Selected TKI (All Comparators)
Global health status/QoL — Very much better106
Global health status/QoL — Moderately better187
Global health status/QoL — A little better66
Global health status/QoL — Unchanged2826
Global health status/QoL — A little worse56
Global health status/QoL — Moderately worse1012
Global health status/QoL — Very much worse27
Physical functioning — Very much better33
Physical functioning — Moderately better1012
Physical functioning — A little better1612
Physical functioning — Unchanged3226
Physical functioning — A little worse78
Physical functioning — Moderately worse106
Physical functioning — Very much worse13
Role functioning — Very much better57
Role functioning — Moderately better107
Role functioning — A little better00
Role functioning — Unchanged5441
Role functioning — A little worse00
Role functioning — Moderately worse47
Role functioning — Very much worse68
Emotional functioning — Very much better910
Emotional functioning — Moderately better76
Emotional functioning — A little better149
Emotional functioning — Unchanged3124
Emotional functioning — A little worse710
Emotional functioning — Moderately worse55
Emotional functioning — Very much worse66
Cognitive functioning — Very much better31
Cognitive functioning — Moderately better138
Cognitive functioning — A little better00
Cognitive functioning — Unchanged4436
Cognitive functioning — A little worse00
Cognitive functioning — Moderately worse1619
Cognitive functioning — Very much worse36
Social functioning — Very much better76
Social functioning — Moderately better146
Social functioning — A little better00
Social functioning — Unchanged5140
Social functioning — A little worse00
Social functioning — Moderately worse47
Social functioning — Very much worse311
Fatigue — Very much better1911
Fatigue — Moderately better1616
Fatigue — A little better00
Fatigue — Unchanged2616
Fatigue — A little worse00
Fatigue — Moderately worse1111
Fatigue — Very much worse716
Nausea and vomiting — Very much better11
Nausea and vomiting — Moderately better75
Nausea and vomiting — A little better00
Nausea and vomiting — Unchanged6748
Nausea and vomiting — A little worse00
Nausea and vomiting — Moderately worse311
Nausea and vomiting — Very much worse15
Pain — Very much better93
Pain — Moderately better1711
Pain — A little better00
Pain — Unchanged4537
Pain — A little worse00
Pain — Moderately worse510
Pain — Very much worse39
Dyspnoea — Very much better119
Dyspnoea — Moderately better00
Dyspnoea — A little better00
Dyspnoea — Unchanged5949
Dyspnoea — A little worse00
Dyspnoea — Moderately worse00
Dyspnoea — Very much worse912
Insomnia — Very much better1410
Insomnia — Moderately better00
Insomnia — A little better00
Insomnia — Unchanged5043
Insomnia — A little worse00
Insomnia — Moderately worse00
Insomnia — Very much worse1517
Appetite loss — Very much better1611
Appetite loss — Moderately better00
Appetite loss — A little better00
Appetite loss — Unchanged5951
Appetite loss — A little worse00
Appetite loss — Moderately worse00
Appetite loss — Very much worse48
Constipation — Very much better814
Constipation — Moderately better00
Constipation — A little better00
Constipation — Unchanged5840
Constipation — A little worse00
Constipation — Moderately worse00
Constipation — Very much worse1316
Diarrhoea — Very much better118
Diarrhoea — Moderately better00
Diarrhoea — A little better00
Diarrhoea — Unchanged6143
Diarrhoea — A little worse00
Diarrhoea — Moderately worse00
Diarrhoea — Very much worse719
Financial difficulties — Very much better1214
Financial difficulties — Moderately better00
Financial difficulties — A little better00
Financial difficulties — Unchanged6349
Financial difficulties — A little worse00
Financial difficulties — Moderately worse00
Financial difficulties — Very much worse47
SecondaryChange From Baseline in EORTC QLQ-CML24 Scales at Week 48 and Week 96

The QLQ-CML24 consists of multi-scale items: symptom burden, impact on worry/mood, impact on daily life, body image problems, satisfaction with care and information and satisfaction with social life. A higher score on most of the item scales in QLQ-CML24 reflects a larger impairment in the corresponding domain, with the exception of the satisfaction with care and information, and problems and satisfaction with social life, where a higher score reflects a higher level of satisfaction.

Time frame:
Baseline, week 48 and week 96.
Reported as:
Count of participants · Participants
Change From Baseline in EORTC QLQ-CML24 Scales at Week 48 and Week 96
ParticipantsAsciminib (All Asciminib)Investigator Selected TKI (All Comparators)
Symptom Burden — Very much better02
Symptom Burden — Moderately better124
Symptom Burden — A little better185
Symptom Burden — Unchanged2722
Symptom Burden — A little worse716
Symptom Burden — Moderately worse612
Symptom Burden — Very much worse75
Impact on Worry/Mood — Very much better117
Impact on Worry/Mood — Moderately better79
Impact on Worry/Mood — A little better206
Impact on Worry/Mood — Unchanged1718
Impact on Worry/Mood — A little worse1611
Impact on Worry/Mood — Moderately worse24
Impact on Worry/Mood — Very much worse411
Impact on Daily Life — Very much better2117
Impact on Daily Life — Moderately better2610
Impact on Daily Life — A little better00
Impact on Daily Life — Unchanged1923
Impact on Daily Life — A little worse00
Impact on Daily Life — Moderately worse65
Impact on Daily Life — Very much worse511
Body Image Problems — Very much better1810
Body Image Problems — Moderately better00
Body Image Problems — A little better00
Body Image Problems — Unchanged4841
Body Image Problems — A little worse00
Body Image Problems — Moderately worse00
Body Image Problems — Very much worse1115
Satisfaction with Care and Information — Very much better813
Satisfaction with Care and Information — Moderately better54
Satisfaction with Care and Information — A little better00
Satisfaction with Care and Information — Unchanged3031
Satisfaction with Care and Information — A little worse00
Satisfaction with Care and Information — Moderately worse187
Satisfaction with Care and Information — Very much worse1611
Satisfaction with Social Life — Very much better1514
Satisfaction with Social Life — Moderately better00
Satisfaction with Social Life — A little better00
Satisfaction with Social Life — Unchanged4037
Satisfaction with Social Life — A little worse00
Satisfaction with Social Life — Moderately worse00
Satisfaction with Social Life — Very much worse2215
PrimaryPercentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)

Molecular response is assessed using BCR-ABL1 transcript levels measured by realtime quantitative polymerase chain reaction. MMR is defined as a ratio BCR-ABL1/ABL ≤0.1% on the international scale (ie, at least 3 log reduction from a standardized baseline value).

Time frame:
At 48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)
ParticipantsAsciminib (Imatinib Stratum)Investigator Selected TKI (Imatinib Stratum)
Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)7041
Statistical analysis
  • Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum) · Mantel Haenszel · p = <0.001 · Risk difference (rd): 29.55 · 95% CI 16.91 to 42.18The Estimate Value is a percentage.

Adverse events

Collected over Adverse events (AEs) are collected from first dose of study treatment until end of study treatment plus 30 days post treatment. AEs reported in this record are from first dose of study treatment until data cut-off on 28-Nov-2023 (approx. 2 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asciminib (All Asciminib)0/200 (0%)22/200 (11%)177/200 (88.5%)
Imatinib0/99 (0%)12/99 (12.1%)89/99 (89.9%)
2nd Generation TKI0/102 (0%)20/102 (19.6%)100/102 (98%)
All Comparators0/201 (0%)32/201 (15.9%)189/201 (94%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventAsciminib (All Asciminib)Imatinib2nd Generation TKIAll Comparators
PneumoniaInfections and infestations0/2001/993/1024/201
COVID-19Infections and infestations0/2000/992/1022/201
Pleural effusionRespiratory, thoracic and mediastinal disorders0/2000/992/1022/201
Atrial fibrillationCardiac disorders0/2001/990/1021/201
Abdominal pain upperGastrointestinal disorders0/2001/990/1021/201
MelaenaGastrointestinal disorders0/2001/990/1021/201
PancreatitisGastrointestinal disorders1/2001/990/1021/201
Pancreatitis acuteGastrointestinal disorders1/2001/990/1021/201
DiverticulitisInfections and infestations0/2001/990/1021/201
Upper respiratory tract infectionInfections and infestations0/2001/991/1022/201
Most frequent other events
Showing 10 of 52
Most frequent other events
EventAsciminib (All Asciminib)Imatinib2nd Generation TKIAll Comparators
AnaemiaBlood and lymphatic system disorders23/20026/9923/10249/201
DiarrhoeaGastrointestinal disorders31/20026/9926/10252/201
HeadacheNervous system disorders26/2008/9922/10230/201
RashSkin and subcutaneous tissue disorders26/20010/9922/10232/201
NauseaGastrointestinal disorders18/20021/9918/10239/201
Neutrophil count decreasedInvestigations29/20016/9921/10237/201
COVID-19Infections and infestations35/20018/9920/10238/201
Muscle spasmsMusculoskeletal and connective tissue disorders4/20019/995/10224/201
Alanine aminotransferase increasedInvestigations14/2006/9919/10225/201
FatigueGeneral disorders28/20014/9918/10232/201

Baseline characteristics

Age, Customized
Age, Customized(Participants)Asciminib (Imatinib Stratum)Asciminib (2nd Generation TKI Stratum)Investigator Selected TKI (Imatinib Stratum)Investigator Selected TKI (2nd Generation TKI Stratum)Total
18 to <65 years69867085310
65 to <75 years2412221270
>= 75 years8210525
Sex: Female, Male
Sex: Female, Male(Participants)Asciminib (Imatinib Stratum)Asciminib (2nd Generation TKI Stratum)Investigator Selected TKI (Imatinib Stratum)Investigator Selected TKI (2nd Generation TKI Stratum)Total
Female39313742149
Male62696560256
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Asciminib (Imatinib Stratum)Asciminib (2nd Generation TKI Stratum)Investigator Selected TKI (Imatinib Stratum)Investigator Selected TKI (2nd Generation TKI Stratum)Total
White63456644218
Black or African American11114
Asian37533456180
Unknown01113
EUTOS Long-Term Survival (ELTS) score
EUTOS Long-Term Survival (ELTS) score(Participants)Asciminib (Imatinib Stratum)Asciminib (2nd Generation TKI Stratum)Investigator Selected TKI (Imatinib Stratum)Investigator Selected TKI (2nd Generation TKI Stratum)Total
Low62606461247
Intermediate30263027113
High91481445
08

Study locations

110 sites
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists Pan
    Tallahassee, Florida 32308, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Uni of Massachusetts Medical Center
    Worcester, Massachusetts 01655, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Williamette Cancer Center
    Eugene, Oregon 97401, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Avera Cancer
    Sioux Falls, South Dakota 57105, United States
  • Chattanooga Onc And Hem Assoc PC
    Chattanooga, Tennessee 37404, United States
  • Texas Oncology
    Amarillo, Texas 79124, United States
  • Texas Oncology-Baylor USO
    Dallas, Texas 75246, United States
  • Texas Oncology
    Dallas, Texas 75251, United States
  • Novartis Investigative Site
    Kingswood, New South Wales 2747, Australia
  • Novartis Investigative Site
    Port Macquarie, New South Wales 2444, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Southport, 4215, Australia
  • Novartis Investigative Site
    Linz, Upper Austria 4010, Austria
  • Novartis Investigative Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Novartis Investigative Site
    Brussels, 1000, Belgium
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Calgary, Alberta T2N 5G2, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8V 1C3, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518037, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450008, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210000, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215004, China
  • Novartis Investigative Site
    Xian, Shanxi 710068, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325000, China
  • Novartis Investigative Site
    Beijing, 100044, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Lanzhou, 730000, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Hradec Králové, 500 05, Czechia
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
  • Novartis Investigative Site
    Copenhagen, 2100, Denmark
  • Novartis Investigative Site
    Helsinki, 00290, Finland
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Kaposvár, 7400, Hungary
  • Novartis Investigative Site
    Kecskemét, 6001, Hungary
  • Novartis Investigative Site
    Delhi, 110085, India
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Reggio Emilia, RE 42123, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4538511, Japan
  • Novartis Investigative Site
    Toyoake, Aichi-ken 4701192, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
  • Novartis Investigative Site
    Kobe, Hyōgo 6500047, Japan
  • Novartis Investigative Site
    Kurashiki, Okayama-ken 7108602, Japan
  • Novartis Investigative Site
    Sakai, Osaka 5900197, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Shimotsuke, Tochigi 3290498, Japan
  • Novartis Investigative Site
    Chūō, Yamanashi 4093898, Japan
  • Novartis Investigative Site
    Akita, 0108543, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Fukushima, 9601295, Japan
  • Novartis Investigative Site
    Osaka, 5458586, Japan
  • Novartis Investigative Site
    Yamagata, 9909585, Japan
  • Novartis Investigative Site
    Kuantan, Pahang 25100, Malaysia
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Subang Jaya, Selangor 47500, Malaysia
  • Novartis Investigative Site
    Kuala Selangor, 68000, Malaysia
  • Novartis Investigative Site
    Amsterdam, North Holland 1081 HV, Netherlands
  • Novartis Investigative Site
    Bergen, NO-5021, Norway
  • Novartis Investigative Site
    Oslo, 0372, Norway
  • Novartis Investigative Site
    Porto, 4200-072, Portugal
  • Novartis Investigative Site
    Vila Nova de Gaia, 4434-502, Portugal
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Košice, 041 90, Slovakia
  • Novartis Investigative Site
    Uijeongbu-si, Gyeonggi-do 11759, South Korea
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Granada, Andalusia 18014, Spain
  • Novartis Investigative Site
    El Palmar, Murcia 30120, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain

Showing the first 100 of 110 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Takahashi N, Kim DW, Kim I, Du X, Lee SE, Hu Y, Kikushige Y, Jiang Q, Wang Y, Chen S, Zhu H, Goto T, Tomita A, Ichii M, Nakamae H, Liu L, Liu B, Malek K, Zhu T, Wu S, Wang J. Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study. Cancer Med. 2026 Jun;15(6):e72019. doi: 10.1002/cam4.72019. PubMed 42339511 ↗
  • Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026 Mar 26;147(13):1433-1446. doi: 10.1182/blood.2025029210. PubMed 41397287 ↗
  • Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. PubMed 38820078 ↗
  • Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec;18(38):4161-4170. doi: 10.2217/fon-2022-0923. Epub 2022 Dec 16. PubMed 36524980 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Nov 2023, 25 months.

Results were first posted in Mar 2025, 1 year 3 months after primary completion.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Jul 21, 2021
StartActual
Oct 6, 2021
Primary completionActual
Nov 28, 2023
CompletionEst.
Jan 18, 2031
Results first posted
Mar 10, 2025
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04971226
Responsible party
Sponsor
First posted
Jul 21, 2021
Start date
Oct 6, 2021
Primary completion
Nov 28, 2023
Completion
Jan 18, 2031 (estimated)
Results posted
Mar 10, 2025
Last update
Aug 28, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion